European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.

Wollenberg, A; Kinberger, M; Arents, B; Aszodi, N; Avila Valle, G; Barbarot, S; Bieber, T; Brough, H A; Calzavara Pinton, P; Christen-Zäch, S; Deleuran, M; Dittmann, M; Dressler, C; Fink-Wagner, A H; Fosse, N; Gáspár, K; Gerbens, L; Gieler, U; Girolomoni, G; Gregoriou, S; ... (2022). European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. Journal of the European Academy of Dermatology and Venereology : JEADV, 36(9), pp. 1409-1431. Wiley 10.1111/jdv.18345

[img]
Preview
Text
Acad_Dermatol_Venereol_-_2022_-_Wollenberg_-_European_guideline_EuroGuiDerm_on_atopic_eczema_part_I_systemic_therapy.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (892kB) | Preview

The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Simon, Dagmar

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1468-3083

Publisher:

Wiley

Language:

English

Submitter:

Pubmed Import

Date Deposited:

19 Aug 2022 10:37

Last Modified:

05 Dec 2022 16:22

Publisher DOI:

10.1111/jdv.18345

PubMed ID:

35980214

Uncontrolled Keywords:

atopic dermatitis atopic eczema

BORIS DOI:

10.48350/172199

URI:

https://boris.unibe.ch/id/eprint/172199

Actions (login required)

Edit item Edit item
Provide Feedback